Skip header and navigation

Refine By

   MORE

10 records – page 1 of 1.

Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats.

https://arctichealth.org/en/permalink/ahliterature54153
Source
J Hypertens. 1999 Nov;17(11):1543-52
Publication Type
Article
Date
Nov-1999
Author
J. Magga
J. Kalliovalkama
H. Romppanen
O. Vuolteenaho
I. Pörsti
M. Kähönen
J P Tolvanen
H. Ruskoaho
Author Affiliation
Department of Pharmacology and Toxicology, University of Oulu, Finland.
Source
J Hypertens. 1999 Nov;17(11):1543-52
Date
Nov-1999
Language
English
Publication Type
Article
Keywords
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Animals
Atrial Natriuretic Factor - genetics
Blood Pressure - drug effects
Cardiomegaly - pathology
Enalapril - pharmacology
Gene Expression - drug effects
Heart - physiopathology
Hypertension - genetics - physiopathology
Losartan - pharmacology
Male
Natriuretic Peptide, Brain
Peptides - genetics
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin - antagonists & inhibitors
Reference Values
Research Support, Non-U.S. Gov't
Abstract
OBJECTIVE: To study the effects of long-term treatment with the type 1 angiotensin (AT1) receptor antagonist losartan and the angiotensin-converting enzyme (ACE) inhibitor enalapril, on cardiac adrenomedullin (ADM), atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) gene expression. METHODS: Spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats were given losartan (15 mg/kg per day) or enalapril (4 mg/kg per day) orally for 10 weeks. The effects of drugs on systolic blood pressure, cardiac hypertrophy, ANP, BNP and ADM mRNA and immunoreactive-ANP (IR)-ANP, IR-BNP and IR-ADM levels in the left ventricle and atria were compared. RESULTS: Losartan and enalapril treatments completely inhibited the increase of systolic blood pressure occurring with ageing in SHR. The ratio of heart to body weight was reduced in both losartan- and enalapril-treated SHR and WKY rats. Treatment with losartan or enalapril reduced left ventricular ANP mRNA and IR-ANP in both strains, and ventricular BNP mRNA levels in SHR rats. Inhibition of ACE, AT1 receptor antagonism, changes in blood pressure or cardiac mass had no effect on left ventricular ADM gene expression in SHR and WKY rats. In addition, atrial IR-ANP and IR-ADM levels increased in SHR whereas IR-BNP levels decreased in WKY and SHR rats in response to drug treatments. CONCLUSIONS: Our results show that ventricular ADM synthesis is an insensitive marker of changes in haemodynamic load or cardiac hypertrophy. Furthermore, the expression of ADM, ANP and BNP genes is differently regulated both in the left ventricle and atria in response to AT1 receptor antagonism and ACE inhibition.
PubMed ID
10608466 View in PubMed
Less detail

[Effect of angiotensin receptor blockers on hemodynamic aspects during myocardial infarction]

https://arctichealth.org/en/permalink/ahliterature53693
Source
Lik Sprava. 2002 Apr-Jun;(3-4):43-4
Publication Type
Article
Author
N A Turubarova
V V Leunov
V K Tashchuk
Source
Lik Sprava. 2002 Apr-Jun;(3-4):43-4
Language
Ukrainian
Publication Type
Article
Keywords
Antihypertensive Agents - pharmacology - therapeutic use
Biphenyl Compounds - pharmacology - therapeutic use
Echocardiography
English Abstract
Hemodynamic Processes - drug effects
Humans
Myocardial Contraction - drug effects
Myocardial Infarction - drug therapy - physiopathology
Receptors, Angiotensin - antagonists & inhibitors
Tetrazoles - pharmacology - therapeutic use
Abstract
As many as 65 patients with myocardial infarction were examined for efficacy of blockers of angiotensin receptors with making use of stress-echocardiography having been instituted on admission and two weeks following treatments administration. Irbesartan has been shown to be highly effective because of its positive impact on myocardial contractility.
PubMed ID
12145889 View in PubMed
Less detail

Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts.

https://arctichealth.org/en/permalink/ahliterature53624
Source
Hypertension. 2003 Jan;41(1):93-8
Publication Type
Article
Date
Jan-2003
Author
Jarkko Piuhola
István Szokodi
Pietari Kinnunen
Mika Ilves
Rudolf deChâtel
Olli Vuolteenaho
Heikki Ruskoaho
Author Affiliation
Department of Pharmacology and Toxicology, Biocenter Oulu, University of Oulu, Oulu, Finland.
Source
Hypertension. 2003 Jan;41(1):93-8
Date
Jan-2003
Language
English
Publication Type
Article
Keywords
Angiotensin II - physiology
Angiotensinogen - genetics
Animals
Animals, Genetically Modified
Benzimidazoles - pharmacology
Endothelin-1 - physiology
Heart Ventricles - metabolism - physiopathology
Humans
Hypertension - complications
Hypertrophy, Left Ventricular - etiology - metabolism - physiopathology
In Vitro
Male
Myocardial Contraction
Organ Culture Techniques
RNA, Messenger - biosynthesis
Rats
Rats, Inbred SHR
Rats, Sprague-Dawley
Receptor, Angiotensin, Type 1
Receptors, Angiotensin - antagonists & inhibitors
Receptors, Endothelin - antagonists & inhibitors
Renin - genetics
Research Support, Non-U.S. Gov't
Stress, mechanical
Sulfonamides - pharmacology
Tetrazoles - pharmacology
Abstract
Endothelin-1 is involved in mechanical load-induced cardiac growth processes; it also has effects on contractility. The interaction of endothelin-1 and the Frank-Starling response is unknown. The present study aimed to characterize the role of endothelin-1 in the regulation of the Frank-Starling response, one of the major mechanisms regulating cardiac contractile force, in both normal and hypertrophied hearts. Nontransgenic rat hearts and hypertrophic hearts of hypertensive double transgenic rats harboring human angiotensinogen and renin genes were studied in a Langendorff isolated heart setup with a liquid-filled balloon inside the left ventricle used to measure contractile parameters. The rats were studied at compensated phase, before showing any signs of heart failure. Compensated hypertrophy in double transgenic rat hearts resulted in improved contractility at a given level of preload when compared with nontransgenic rat hearts. Hearts of both rat lines showed preserved Frank-Starling responses, that is, increased contractile function in response to increased end-diastolic pressure. The mixed endothelin A/B receptor antagonist bosentan attenuated the Frank-Starling response by 53% (P
PubMed ID
12511536 View in PubMed
Less detail

General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.

https://arctichealth.org/en/permalink/ahliterature76293
Source
Br J Clin Pharmacol. 2005 Nov;60(5):526-33
Publication Type
Article
Date
Nov-2005
Author
Torben Dybdahl
Morten Andersen
Jakob Kragstrup
Ivar Sønbø Kristiansen
Jens Søndergaard
Author Affiliation
Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, J.B. Winsløws Vej. 9, DK-5000 Odense, Denmark.
Source
Br J Clin Pharmacol. 2005 Nov;60(5):526-33
Date
Nov-2005
Language
English
Publication Type
Article
Keywords
Adult
Aged
Anti-Ulcer Agents - therapeutic use
Attitude of Health Personnel
Consumer Satisfaction
Cyclooxygenase 2 Inhibitors - therapeutic use
Denmark
Diffusion of Innovation
Drug Utilization
Family Practice - trends
Female
Humans
Male
Middle Aged
Omeprazole - therapeutic use
Physician's Practice Patterns - trends
Receptors, Angiotensin - antagonists & inhibitors
Regression Analysis
Research Support, Non-U.S. Gov't
Tryptamines - therapeutic use
Abstract
AIM: To test the hypothesis that general practitioners (GPs) with high prescribing levels of certain drugs will adopt new drugs belonging to the same therapeutic group faster than those with low prescribing levels. METHODS: The adoption of four new drugs: esomeprazol, selective cyclo-oxygenase-2 inhibitors, new triptans, and angiotensin-II receptor blockers were analysed using population-based prescription data. We used the preference proportion (prescriptions for new rather than older alternatives for the same indication) to measure GPs' adoption rate. Annual prescribing volume and prevalence were used to measure previous prescribing of older drug alternatives. We modelled the preference proportion using multiple linear regression analysis and the prescribing of older drugs as independent variables. We controlled for the GPs' general prescribing level and weighted for practice size. In the first three analyses, we dichotomized data using the median, lower and upper quartile as cut-off point. Next, we grouped data into quartiles and finally, we used continuous data. RESULTS: For esomeprazol and new triptans there was a higher preference for new drugs among "high prescribers", but only when this term was defined as the upper quarter and the upper half of previous prescribing levels, respectively (mean difference in preference proportion: 10.2% (99% confidence interval = 1.3%, 19.1%) and 8.2% (0.2%, 16.2%)). For the remaining two drug classes the associations were weak and almost all statistically nonsignificant. CONCLUSION: There is no consistent association between GPs' level of drug prescribing and their adoption of new drugs of the same therapeutic group.
Notes
Comment In: Br J Clin Pharmacol. 2005 Nov;60(5):457-816236034
PubMed ID
16236043 View in PubMed
Less detail

Inhibitory effect of losartan on laser-induced choroidal neovascularization in rats.

https://arctichealth.org/en/permalink/ahliterature50803
Source
Am J Ophthalmol. 2001 Oct;132(4):587-9
Publication Type
Article
Date
Oct-2001
Author
T. Hikichi
F. Mori
A. Takamiya
M. Sasaki
Y. Horikawa
M. Takeda
A. Yoshida
Author Affiliation
Department of Ophthalmology, Asahikawa Medical College, 2-1 Midorigaoka-higashi, Asahikawa, 078-8510, Japan. hikichi@asahikawa-med.ac.jp
Source
Am J Ophthalmol. 2001 Oct;132(4):587-9
Date
Oct-2001
Language
English
Publication Type
Article
Keywords
Animals
Choroid - surgery
Choroidal Neovascularization - etiology - pathology - prevention & control
Fluorescein Angiography
Laser Coagulation
Losartan - therapeutic use
Male
Models, Animal
Rats
Rats, Inbred BN
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin - antagonists & inhibitors
Abstract
PURPOSE: To investigate the inhibitory effects of losartan, an angiotensin receptor antagonist, on angiogenesis in a rat model of laser-induced choroidal neovascularization. METHODS: Experimental study. Fifteen Brown-Norway male rats received losartan (approximately 5 mg/kg/d) in drinking water, and 15 Brown-Norway male rats received unsupplemented drinking water 1 week before photocoagulation, and it was continued to the end of the study. Two weeks after intense laser photocoagulation, choroidal neovascularization was evaluated by fluorescein angiography and histopathologic evaluation. RESULTS: The incidence of choroidal neovascularization formation was 99.5 +/-.2% (mean +/- standard deviation) in controls and 72.5 +/- 8.8% in losartan-treated rats (P
PubMed ID
11589891 View in PubMed
Less detail

Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

https://arctichealth.org/en/permalink/ahliterature10016
Source
J Hypertens. 2002 Apr;20(4):657-63
Publication Type
Article
Date
Apr-2002
Author
Kurland L
Melhus H
Karlsson J
Kahan T
Malmqvist K
Ohman P
Nyström F
Hägg A
Lind L
Author Affiliation
Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden. lisa.kurland@medsci.uu.se
Source
J Hypertens. 2002 Apr;20(4):657-63
Date
Apr-2002
Language
English
Publication Type
Article
Keywords
Aged
Alleles
Angiotensinogen - genetics
Antihypertensive Agents - therapeutic use
Atenolol - therapeutic use
Biphenyl Compounds - therapeutic use
Female
Humans
Hypertension - drug therapy - genetics - pathology
Hypertrophy, Left Ventricular - drug therapy - genetics - pathology
Male
Middle Aged
Polymorphism, Genetic
Receptor, Angiotensin, Type 1
Receptors, Angiotensin - antagonists & inhibitors - genetics
Renin-Angiotensin System - genetics
Research Support, Non-U.S. Gov't
Sweden
Tetrazoles - therapeutic use
Abstract
BACKGROUND: Our aim was to determine if gene polymorphisms in the renin-angiotensin-aldosterone system (RAAS) were related to the degree of change in left ventricular hypertrophy (LVH) during antihypertensive treatment. METHODS AND RESULTS: Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months. The angiotensinogen T174M and M235T, the angiotensin-converting enzyme I/D, the AT1-receptor A1166C and the aldosterone synthase (CYP11B2) -344 C/T polymorphisms were analysed and related to the change in left ventricular mass (LVM). Patients with the angiotensinogen 174 TM genotype treated with irbesartan responded with the greatest reduction in LVM (-23 +/- 31SD g/m2 for TM and +0.5 +/- 18 g/m2 for TT, P = 0.005), independent of blood pressure reduction. Both the angiotensinogen 235 T-allele (P = 0.02) and the AT1-receptor 1166 AC genotype responded with the greatest reduction in LVM when treated with irbesartan (-0.1 +/- 19 g/m2 for AA and -18 +/- 30 g/m2 for AC, P = 0.02), independent of blood pressure reduction. These polymorphisms were not associated with the change in LVM during treatment with atenolol. DISCUSSION: The angiotensinogen T174M and M235T and the AT1-receptor A1166C polymorphisms were related to the change in LVH during antihypertensive treatment with an AT1-receptor antagonist; of these angiotensinogen T174M was the most powerful. This highlights the role of the RAAS for left ventricular hypertrophy and the potential of pharmacogenetics as a tool for guidance of antihypertensive therapy.
Notes
Comment In: J Hypertens. 2002 Apr;20(4):583-511910285
PubMed ID
11910301 View in PubMed
Less detail

Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure.

https://arctichealth.org/en/permalink/ahliterature53360
Source
J Am Coll Cardiol. 2004 Apr 21;43(8):1473-80
Publication Type
Article
Date
Apr-21-2004
Author
Yun-He Liu
Xiao-Ping Yang
Edward G Shesely
Steadman S Sankey
Oscar A Carretero
Author Affiliation
Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA.
Source
J Am Coll Cardiol. 2004 Apr 21;43(8):1473-80
Date
Apr-21-2004
Language
English
Publication Type
Article
Keywords
Animals
Disease Models, Animal
Heart Failure, Congestive - etiology - metabolism
Heart Function Tests
Kinins - metabolism
Male
Myocardial Infarction - complications
Rats
Rats, Inbred BN
Receptors, Adrenergic, beta-2 - antagonists & inhibitors - metabolism
Receptors, Angiotensin - antagonists & inhibitors - metabolism
Research Support, U.S. Gov't, P.H.S.
Abstract
OBJECTIVES: We studied the role of angiotensin II type 2 (AT(2)) receptors and kinins in the cardioprotective effect of angiotensin II type 1 antagonists (AT(1)-ant) in rats with heart failure (HF) after myocardial infarction. BACKGROUND: The AT(1)-ant is as effective as angiotensin-converting enzyme inhibitors in treating HF, but the mechanisms whereby AT(1)-ant exert their benefits on HF in vivo are more complex than previously understood. METHODS: Brown Norway Katholiek rats (BNK), which are deficient in kinins because of a mutation in the kininogen gene, and their wild-type control (Brown Norway [BN]) underwent myocardial infarction. Two months later, they were treated for two months with: 1) vehicle; 2) AT(1)-ant (L158809, Merck, Rahway, New Jersey); 3) AT(1)-ant + AT(2)-ant (PD-123319, Parke Davis, Ann Arbor, Michigan); or 4) AT(1)-ant + kinin B(2) receptor antagonist (B(2)-ant) (icatibant) (only BN). We measured left ventricular weight (LVW) gravimetrically, myocyte cross-sectional area (MCSA) and interstitial collagen fraction (ICF) histologically, and ejection fraction by ventriculography. RESULTS: Development of HF was comparable in BN and BNK rats. The AT(1)-ant reduced LVW and MCSA and the AT(2)-ant blocked these effects in BN rats, but the B(2)-ant did not. The AT(1)-ant reduced LVW and MCSA in BNK rats, and this effect was reversed by the AT(2)-ant. In BN rats, ICF was reduced and LVEF increased by AT(1)-ant, and both AT(2)-ant and B(2)-ant reversed these effects. In BNK rats, the AT(1)-ant failed to reduce ICF, and its therapeutic effect on LVEF was significantly blunted. CONCLUSIONS: In HF, the AT(2) receptor plays an important role in the therapeutic effects of AT(1)-ant, and this effect may be mediated partly through kinins; however, kinins appear to play a lesser role in the antihypertrophic effect of AT(1)-ant.
PubMed ID
15093886 View in PubMed
Less detail

[The outlook for the use of the nonpeptide angiotensin II-receptor antagonist losartan in treating heart failure]

https://arctichealth.org/en/permalink/ahliterature54184
Source
Eksp Klin Farmakol. 1999 Jul-Aug;62(4):77-80
Publication Type
Article

[Use of isosorbide dinitrate and antagonists of angiotensin II in patients with stable angina pectoris in early stages of cardiac insufficiency]

https://arctichealth.org/en/permalink/ahliterature10160
Source
Lik Sprava. 2001 Mar-Apr;(2):146-8
Publication Type
Article
Author
S E Lozyns'kyi
I S Abushaira
Source
Lik Sprava. 2001 Mar-Apr;(2):146-8
Language
Ukrainian
Publication Type
Article
Keywords
Angina Pectoris - diagnosis - drug therapy - physiopathology
Angiotensin II - metabolism
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Drug Therapy, Combination
Enalapril - therapeutic use
English Abstract
Humans
Isosorbide Dinitrate - therapeutic use
Losartan - therapeutic use
Myocardial Ischemia - diagnosis - drug therapy - physiopathology
Prognosis
Receptors, Angiotensin - antagonists & inhibitors
Vasodilator Agents - therapeutic use
Ventricular Function, Left
Abstract
Effects were studied of isosorbite dinitrate and antagonists of angiotensin II in patients with stable angina presenting with incipient stages of cardiac insufficiency. Changes in the ejection fraction, phases in passive and active filling of the left ventricle can be used as a prognostic criterion for efficiency of a long-term combined therapy involving the use of isosorbid dinitrate and renitec or cozaar.
PubMed ID
11519419 View in PubMed
Less detail

10 records – page 1 of 1.